Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Julien Crettaz is active.

Publication


Featured researches published by Julien Crettaz.


Gut | 2011

Oxaliplatin in combination with liver-specific expression of interleukin 12 reduces the immunosuppressive microenvironment of tumours and eradicates metastatic colorectal cancer in mice

Manuela Gonzalez-Aparicio; Pilar Alzuguren; Itsaso Mauleón; José Medina-Echeverz; Sandra Hervas-Stubbs; Uxua Mancheño; Pedro Berraondo; Julien Crettaz; Gloria González-Aseguinolaza; Jesús Prieto; Ruben Hernandez-Alcoceba

Background and aims New options are needed for the management and prevention of colorectal cancer liver metastases. Interleukin 12 (IL-12) is an immunostimulatory cytokine with proven antitumour effect in animal models. Despite evidence indicating its biological effect in humans, neither the recombinant protein nor gene therapy vectors expressing IL-12 have shown a relevant benefit in patients with cancer. Objective To develop a new approach to overcome the difficulties in obtaining a suitable expression pattern and the immunosuppressive milieu in the tumours which contribute to this poor performance. Methods A high-capacity (‘gutless’) adenoviral vector carrying a liver-specific, mifepristone (Mif)-inducible system for the expression of IL-12 (HC-Ad/RUmIL-12) was used in combination with chemotherapy. Tumours were established in the liver of C57BL/6 mice by inoculation of MC38 colon cancer cells. Results Intrahepatic injection of HC-Ad/RUmIL-12 and tailored induction regimens allowed the maintenance of safe and efficient levels of IL-12 in vivo. An individualised, stepwise increase in the dose of Mif (125–4000 μg/kg) was needed to compensate for the progressive but transient downregulation of the inducible system. Repeated cycles of Mif induction (every 24 h for 10 days) were needed for optimal tumour eradication. However, complete protection against tumour rechallenge was seen in <25% of the animals. The administration of oxaliplatin (5 mg/kg intraperitoneally) 3 days before starting the induction regimen achieved efficient elimination of liver metastases with a single cycle of IL-12 induction, and improved protection against tumour rechallenge. This was associated with a shift in the tumour microenvironment towards a more pro-immunogenic phenotype, with an increase in the CD8+/T regulatory cell ratio and a reduction in myeloid-derived suppressor cells. These effects were not seen with 5-fluorouracil, irinotecan or gemcitabine. Conclusions Long-term controlled expression of IL-12 using an HC-Ad vector in combination with oxaliplatin is effective and clinically applicable against hepatic colon cancer metastases.


Human Gene Therapy | 2009

Effect of Adeno-Associated Virus Serotype and Genomic Structure on Liver Transduction and Biodistribution in Mice of Both Genders

Astrid Pañeda; Lucia Vanrell; Itsaso Mauleón; Julien Crettaz; Pedro Berraondo; Eric J. Timmermans; Stuart G. Beattie; Jaap Twisk; Sander J. H. van Deventer; Jesús Prieto; Antonio Fontanellas; Maria Sol Rodríguez-Peña; Gloria González-Aseguinolaza

Recombinant adeno-associated viral (AAV) vectors have unique properties, which make them suitable vectors for gene transfer. Here we assess the liver transduction efficiency and biodistribution of AAV-pseudotyped capsids (serotypes) 1, 5, 6, and 8, combined with single-stranded and double-stranded genomic AAV2 structures carrying the luciferase reporter gene after systemic administration. The analysis was performed in vivo and ex vivo, in male and female mice. Gender-related differences in AAV-mediated transduction and biodistribution were shown for the four serotypes. Our data confirm the superiority of AAV8 over the rest of the serotypes, as well as a significant advantage of double-stranded genomes in terms of liver transduction efficiency, particularly in females. Regarding biodistribution, AAV5 displayed a narrower tropism than the other serotypes tested, transducing, almost exclusively, the liver. Interestingly, AAV1 and AAV8, in particular those having single-stranded genomes, showed high transduction efficiency of female gonads. However, no inadvertent germ line transmission of AAV genomes was observed after breeding single-stranded AAV8-injected female mice with untreated males. In conclusion, double-stranded AAV8 vectors led to the highest levels of liver transduction in mice, as demonstrated by luciferase expression. Nevertheless, the transduction of other organs with AAV8 vectors could favor the use of less efficient serotypes, such as AAV5, which display a narrow tropism.


Journal of Virology | 2009

Treatment of Chronic Viral Hepatitis in Woodchucks by Prolonged Intrahepatic Expression of Interleukin-12

Julien Crettaz; Itziar Otano; Laura Ochoa; Alberto Benito; Astrid Pañeda; Igor Aurrekoetxea; Pedro Berraondo; Juan R. Rodriguez-Madoz; Aurora Astudillo; Florian Kreppel; Stefan Kochanek; J.J. Ruiz; Stephan Menne; Jesús Prieto; Gloria González-Aseguinolaza

ABSTRACT Chronic hepatitis B is a major cause of liver-related death worldwide. Interleukin-12 (IL-12) induction accompanies viral clearance in chronic hepatitis B virus infection. Here, we tested the therapeutic potential of IL-12 gene therapy in woodchucks chronically infected with woodchuck hepatitis virus (WHV), an infection that closely resembles chronic hepatitis B. The woodchucks were treated by intrahepatic injection of a helper-dependent adenoviral vector encoding IL-12 under the control of a liver-specific RU486-responsive promoter. All woodchucks with viral loads below 1010 viral genomes (vg)/ml showed a marked and sustained reduction of viremia that was accompanied by a reduction in hepatic WHV DNA, a loss of e antigen and surface antigen, and improved liver histology. In contrast, none of the woodchucks with higher viremia levels responded to therapy. The antiviral effect was associated with the induction of T-cell immunity against viral antigens and a reduction of hepatic expression of Foxp3 in the responsive animals. Studies were performed in vitro to elucidate the resistance to therapy in highly viremic woodchucks. These studies showed that lymphocytes from healthy woodchucks or from animals with low viremia levels produced gamma interferon (IFN-γ) upon IL-12 stimulation, while lymphocytes from woodchucks with high viremia failed to upregulate IFN-γ in response to IL-12. In conclusion, IL-12-based gene therapy is an efficient approach to treat chronic hepadnavirus infection in woodchucks with viral loads below 1010 vg/ml. Interestingly, this therapy is able to break immunological tolerance to viral antigens in chronic WHV carriers.


Hepatology | 2006

Intrahepatic injection of adenovirus reduces inflammation and increases gene transfer and therapeutic effect in mice.

Julien Crettaz; Pedro Berraondo; Itsaso Mauleón; Laura Ochoa; Vijay Shankar; Miguel Barajas; Nico van Rooijen; Stefan Kochanek; Cheng Qian; Jesús Prieto; Ruben Hernandez-Alcoceba; Gloria González-Aseguinolaza

Recombinant adenoviruses (Ad) are among the most extensively used vectors for liver gene transfer. One of the major limitations for the clinical application of these vectors is the inflammatory immune response associated with systemic administration of high dose of virus. We evaluated the effect of Ad administration route on the inflammatory immune response and liver transgene expression. We compared direct intrahepatic injection (IH) with the systemic administration via tail vein (IV). IH injection of Ad resulted in a lower inflammatory response and a higher transgene expression. When a relatively low dose of virus was used, IV administration resulted in no detectable protein expression but production of proinflammatory cytokines. In contrast, IH administration induced high levels of transgene expression and no inflammation, although we detected a transient hypertransaminemia, which fully resolved within days. Furthermore, IH injection resulted in a faster protein expression being more intense at the site of injection, whereas IV administration caused slower but diffuse liver expression. IH injection also reduced the spreading of the virus to other organs. Independently of the route, depletion of Kupffer cells significantly enhanced the transduction efficiency of Ad. This effect was stronger when using IV injection, indicating that IH injection partially overcomes Kupffer cell phagocytic activity. Moreover, the antitumor efficacy of high‐capacity‐Ad encoding murine interleukin‐12 (IL‐12) was significantly greater when the vector was administered by IH injection than when given IV. In conclusion, IH injection of adenovirus represents a safe and efficient administration route for clinical applications of gene therapy targeting the liver. (HEPATOLOGY 2006.)


Molecular Cancer | 2009

Evaluation of bioluminescent imaging for noninvasive monitoring of colorectal cancer progression in the liver and its response to immunogene therapy

Maider Zabala; Pilar Alzuguren; Carolina Benavides; Julien Crettaz; Gloria González-Aseguinolaza; Carlos Ortiz de Solórzano; Manuela Gonzalez-Aparicio; M.G. Kramer; Jesús Prieto; Ruben Hernandez-Alcoceba

BackgroundBioluminescent imaging (BLI) is based on the detection of light emitted by living cells expressing a luciferase gene. Stable transfection of luciferase in cancer cells and their inoculation into permissive animals allows the noninvasive monitorization of tumor progression inside internal organs. We have applied this technology for the development of a murine model of colorectal cancer involving the liver, with the aim of improving the pre-clinical evaluation of new anticancer therapies.ResultsA murine colon cancer cell line stably transfected with the luciferase gene (MC38Luc1) retains tumorigenicity in immunocompetent C57BL/6 animals. Intrahepatic inoculation of MC38Luc1 causes progressive liver infiltration that can be monitored by BLI. Compared with ultrasonography (US), BLI is more sensitive, but accurate estimation of tumor mass is impaired in advanced stages. We applied BLI to evaluate the efficacy of an immunogene therapy approach based on the liver-specific expression of the proinflammatory cytokine interleukin-12 (IL-12). Individualized quantification of light emission was able to determine the extent and duration of antitumor responses and to predict long-term disease-free survival.ConclusionWe show that BLI is a rapid, convenient and safe technique for the individual monitorization of tumor progression in the liver. Evaluation of experimental treatments with complex mechanisms of action such as immunotherapy is possible using this technology.


Journal of Virology | 2009

Semliki Forest Virus Expressing Interleukin-12 Induces Antiviral and Antitumoral Responses in Woodchucks with Chronic Viral Hepatitis and Hepatocellular Carcinoma

Juan R. Rodriguez-Madoz; Katherine H. Liu; Jose I. Quetglas; Marta Ruiz-Guillen; Itziar Otano; Julien Crettaz; Scott D. Butler; Christine A. Bellezza; Nathan L. Dykes; Bud C. Tennant; Jesús Prieto; Gloria González-Aseguinolaza; Cristian Smerdou; Stephan Menne

ABSTRACT A vector based on Semliki Forest virus (SFV) expressing high levels of interleukin-12 (SFV-enhIL-12) has previously demonstrated potent antitumoral efficacy in small rodents with hepatocellular carcinoma (HCC) induced by transplantation of tumor cells. In the present study, the infectivity and antitumoral/antiviral effects of SFV vectors were evaluated in the clinically more relevant woodchuck model, in which primary HCC is induced by chronic infection with woodchuck hepatitis virus (WHV). Intratumoral injection of SFV vectors expressing luciferase or IL-12 resulted in high reporter gene activity within tumors and cytokine secretion into serum, respectively, demonstrating that SFV vectors infect woodchuck tumor cells. For evaluating antitumoral efficacy, woodchuck tumors were injected with increasing doses of SFV-enhIL-12, and tumor size was measured by ultrasonography following treatment. In five (83%) of six woodchucks, a dose-dependent, partial tumor remission was observed, with reductions in tumor volume of up to 80%, but tumor growth was restored thereafter. Intratumoral treatment further produced transient changes in WHV viremia and antigenemia, with ≥1.5-log10 reductions in serum WHV DNA in half of the woodchucks. Antitumoral and antiviral effects were associated with T-cell responses to tumor and WHV antigens and with expression of CD4 and CD8 markers, gamma interferon, and tumor necrosis factor alpha in peripheral blood mononuclear cells, suggesting that immune responses against WHV and HCC had been induced. These experimental observations suggest that intratumoral administration of SFV-enhIL-12 may represent a strategy for treatment of chronic HBV infection and associated HCC in humans but indicate that this approach could benefit from further improvements.


Hepatology | 2012

Modulation of regulatory T-cell activity in combination with interleukin-12 increases hepatic tolerogenicity in woodchucks with chronic hepatitis B†‡

Itziar Otano; Lester Suarez; Javier Dotor; Manuela Gonzalez-Aparicio; Julien Crettaz; Cristina Olagüe; Africal Vales; José Ignacio Riezu; Esther Larrea; Francisco Borrás; Alberto Benito; Ruben Hernandez-Alcoceba; Stephan Menne; Jesús Prieto; Gloria González-Aseguinolaza

Regulatory T cells (Treg) play a critical role in the modulation of immune responses to viral antigens in chronic viral hepatitis. Woodchucks (Marmota monax) infected with the woodchuck hepatitis virus (WHV) represent the best animal model for chronic hepatitis B virus (HBV) infection. Examination of intrahepatic and peripheral Treg in uninfected and WHV chronically infected woodchucks showed a significant increase of intrahepatic Treg numbers in chronically infected animals, whereas no differences were found in peripheral blood. In agreement with these data, higher expression levels of Forkhead box P3 (Foxp3), interleukin (IL)‐10, transforming growth factor beta (TGF‐β) were detected in the liver of chronic WHV carriers in comparison to uninfected animals. Furthermore, treatment of WHV‐infected animals with an adenovirus encoding IL‐12 failed to reduce viral load, a finding that was associated with lymphocyte unresponsiveness to IL‐12 stimulation in vitro. We observed that TGF‐β and Treg play a major role in the lack of lymphocyte response to IL‐12 stimulation, as TGF‐β inhibition and Treg depletion allowed recovery of T‐cell responsiveness to this cytokine. Based on these results, woodchucks were treated with IL‐12 in combination with a TGF‐β inhibitory peptide or Treg depletion. However, no antiviral effect was achieved and, instead, an enhancement of the intrahepatic tolerogenic environment was observed. Conclusion: Our data show that TGF‐β inhibition or Treg depletion had no added benefit over IL‐12 therapy in chronic WHV infection. IL‐12 immunostimulation induces a strong immunosuppressive reaction in the liver of chronic WHV carriers that counteracts the antiviral effect of the treatment. (HEPATOLOGY 2012)


Journal of Gene Medicine | 2008

Characterization of high-capacity adenovirus production by the quantitative real-time polymerase chain reaction: a comparative study of different titration methods

Julien Crettaz; Cristina Olagüe; Africa Vales; Igor Aurrekoetxea; Pedro Berraondo; Itziar Otano; Stephan Kochanek; Jesús Prieto; Gloria González-Aseguinolaza

High‐capacity adenoviruses (HC‐Ad) hold great promise for the treatment of many diseases. The major drawbacks for the clinical application of this vector concern difficulties with respect to large‐scale production, and the absence of standardized methods for production and titration. In the present study, we compare the different methods found in the literature for characterizing HC‐Ad production.


Expert Opinion on Biological Therapy | 2006

Gene therapy for viral hepatitis

Gloria González-Aseguinolaza; Julien Crettaz; Laura Ochoa; Itziar Otano; Rafael Aldabe; Astrid Pañeda

Hepatitis B and C infections are two of the most prevalent viral diseases in the world. Existing therapies against chronic viral hepatitis are far from satisfactory due to low response rates, undesirable side effects and selection of resistant viral strains. Therefore, new therapeutic approaches are urgently needed. This review, after briefly summarising the in vitro and in vivo systems for the study of both diseases and the genetic vehicles commonly used for liver gene transfer, examines the existing status of gene therapy-based antiviral strategies that have been employed to prevent, eliminate or reduce viral infection. In particular, the authors focus on the results obtained in clinical trials and experimental clinically relevant animal models.


Journal of Hepatology | 2006

37 Gene therapy of chronic hepatitis B infection using a high-capacity adenovirus expressing interleukin 12 under the control of a liver specific mifepristone-inducible promoter

Julien Crettaz; Laura Ochoa; Astrid Pañeda; C. Olagüe; A. Vales; Stefan Kochanek; Jesús Prieto; Gloria González-Aseguinolaza

Three hundred fifty millions people are estimated to be infected by the hepatitis B virus (HBV). Eighty-seven millions of them would develop HBV-related liver cancer or cirrhosis. In this study we developed a high-capacity adenovirus (HC-Ad), characterized by its low toxicity and long-term expression, encoding for the murine interleukin 12 (mIL12) directed by a liver-specific promoter and inducible by the administration of mifepristone (HC-RU-mIL12). We assayed its antiviral effect using two animal models of chronic HBV infection: transgenic mice for the HBV genome and woodchucks chronically infected by the woodchuck hepatitis virus (WHV).

Collaboration


Dive into the Julien Crettaz's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar

Gloria González-Aseguinolaza

Chartered Institute of Management Accountants

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Stephan Menne

Georgetown University Medical Center

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge